Q1 EPS Estimates for Henry Schein Lowered by Zacks Research

Henry Schein, Inc. (NASDAQ:HSIC) – Zacks Research decreased their Q1 2026 earnings per share estimates for shares of Henry Schein in a research note issued to investors on Tuesday, March 17th. Zacks Research analyst Team now expects that the company will earn $1.20 per share for the quarter, down from their prior estimate of $1.22. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein’s Q3 2026 earnings at $1.43 EPS, Q4 2026 earnings at $1.44 EPS, FY2026 earnings at $5.26 EPS, Q1 2027 earnings at $1.28 EPS, Q2 2027 earnings at $1.38 EPS, Q3 2027 earnings at $1.49 EPS, Q4 2027 earnings at $1.62 EPS, FY2027 earnings at $5.76 EPS and FY2028 earnings at $6.28 EPS.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.30 by $0.04. The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.Henry Schein’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period last year, the company earned $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS.

Other equities analysts have also recently issued reports about the stock. Barclays started coverage on shares of Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective for the company. UBS Group boosted their target price on shares of Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Leerink Partners restated a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Mizuho raised their price target on shares of Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Finally, Wells Fargo & Company lifted their price objective on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $85.58.

Henry Schein Trading Down 0.6%

Shares of NASDAQ:HSIC opened at $72.68 on Thursday. The business’s 50 day moving average price is $77.83 and its 200-day moving average price is $72.96. Henry Schein has a 1 year low of $60.56 and a 1 year high of $89.29. The firm has a market capitalization of $8.34 billion, a price-to-earnings ratio of 22.23, a price-to-earnings-growth ratio of 2.16 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76.

Insider Buying and Selling

In other Henry Schein news, EVP Mark E. Mlotek sold 5,925 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total transaction of $478,740.00. Following the transaction, the executive vice president owned 80,554 shares of the company’s stock, valued at approximately $6,508,763.20. The trade was a 6.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Philip A. Laskawy sold 2,844 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $80.36, for a total value of $228,543.84. Following the completion of the sale, the director owned 21,961 shares of the company’s stock, valued at approximately $1,764,785.96. The trade was a 11.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 104,556 shares of company stock valued at $8,476,351 over the last ninety days. 1.08% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Ameriprise Financial Inc. grew its holdings in shares of Henry Schein by 3,275.2% in the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares during the period. Bank of Montreal Can increased its position in Henry Schein by 3,655.7% during the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock worth $162,102,000 after purchasing an additional 2,087,666 shares during the last quarter. Norges Bank purchased a new position in Henry Schein during the second quarter worth about $89,476,000. M.D. Sass LLC acquired a new position in Henry Schein in the 2nd quarter valued at about $79,201,000. Finally, Schroder Investment Management Group boosted its holdings in Henry Schein by 149.3% in the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after purchasing an additional 936,471 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein News Roundup

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Zacks raised FY2027 and FY2026 EPS outlooks (FY2027 to $5.76 from $5.68; FY2026 to $5.26 from $5.23), implying better medium‑term earnings trajectory and alignment with Henry Schein’s FY2026 guidance — a supportive sign for forward valuation and investor confidence.
• Positive Sentiment: Zacks bumped several later‑quarter estimates (Q4 2027 to $1.62, Q3 2027 to $1.49, Q4 2026 to $1.44, Q3 2026 to $1.43), signaling expected revenue/earnings strength beyond the immediate quarters.
• Positive Sentiment: Industry recognition: Henry Schein was named one of Ethisphere’s 2026 World’s Most Ethical Companies for the 15th consecutive year — a reputational positive that can help customer/partner retention and long‑term brand value. Ethisphere Recognition
• Positive Sentiment: Zacks published a positive research feature highlighting Henry Schein as a strong growth stock, which may support longer‑term investor interest and flows into the name. Zacks Feature
• Neutral Sentiment: Zacks issued an FY2028 EPS projection of $6.28 — constructive for long‑run expectations but distant and therefore less immediately market‑moving.
• Negative Sentiment: Zacks trimmed near‑term estimates: Q1 2027 EPS lowered to $1.28 from $1.35, suggesting softer results or timing shifts that can pressure short‑term sentiment.
• Negative Sentiment: Zacks cut Q2 2027 EPS to $1.38 from $1.47, another near‑term downgrade that increases uncertainty around upcoming quarters.
• Negative Sentiment: Zacks modestly lowered Q1 2026 EPS to $1.20 from $1.22, reinforcing the mixed near‑term view and likely contributing to intraday selling.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.